Jylamvo J Code: J8611

Drug & Product Overview

HCPCS Descriptor Methotrexate (jylamvo), oral, 2.5 mg

HCPCS Added Date July 1, 2024

Manufacturer Shorla Oncology

Route of Administration Oral

Generic Status Single-Source; Branded

Dosage Form Solution

About Jylamvo

Jylamvo is a medication aligned to the HCPCS J Code: J8611 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the oral route and manufactured by Shorla Oncology.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
81927-0204-01	Jylamvo	SHORLA ONCOLOGY INC.	48	120 MG / 60 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Jylamvo Pricing & Reimbursement

J8611 Private Payer Reimbursement

$19.05 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q4 2026

Methotrexate 505(b)(2) Information:

HCPCS Code	Manufacturer	Active Ingredient	HCPCS Description
J8610	Generic Code (Multiple Manufacturers)	Methotrexate	Methotrexate; oral, 2.5 mg
J8611	Shorla Oncology	Methotrexate	Methotrexate (jylamvo), oral, 2.5 mg
J8612	Azurity Pharmaceuticals	Methotrexate	Methotrexate (xatmep), oral, 2.5 mg

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Jylamvo Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Acute lymphoblastic leukemia Mycosis fungoides (cutaneous T-cell lymphoma) Polyarticular juvenile idiopathic arthritis Relapsed or refractory non-Hodgkin lymphomas Rheumatoid arthritis Severe psoriasis

Drug Class

Folate Analog Metabolic Inhibitor [EPC]Folic Acid Metabolism Inhibitors [MoA]

Frequently Asked Questions

Is there an available Jylamvo billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for Jylamvo.

Are there any available Jylamvo patient assistance programs?

Jylamvo patient assistance information can be found through Shorla Oncology Inc.. Visit Here →

Where can I find Jylamvo prescribing information?

Jylamvo prescribing information can be found at the link below: Visit Here →

Where can I find Jylamvo side effect information?

Our team did not identify a source of side effect information for Jylamvo.

Does billing Jylamvo require JZ/JW wastage modifiers?

CMS does not include Jylamvo (J8611) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J8611. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.